Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      SWK Holdings Corporation Announces Financial Results for First Quarter 2020

      Conference Call and Live Audio Webcast Scheduled for Friday, May 15, 2020, at 10:00 a.m. ET


      News provided by

      SWK Holdings Corporation

      May 14, 2020, 16:05 ET

      Share this article

      Share this article


      DALLAS, May 14, 2020 /PRNewswire/ --

      Corporate Highlights

      • Core specialty finance segment generated an 11.3% adjusted ROIC, and yielding assets increased to $179.2 million, a 15.7% increase in comparison to the quarter ended March 31, 2019
      • Rajiv Khosla, Ph.D. appointed as Chief Executive Officer of Enteris BioPharma
      • SWK Holdings common stock uplisted to Nasdaq Capital Market
      • Board of Directors authorized $2.0 million stock repurchase program

      First Quarter 2020 Financial Highlights

      • Total revenue for the quarter ended March 31, 2020 was $7.3 million, a 22% decrease from $9.4 million for the quarter ended March 31, 2019
      • Quarterly GAAP net loss of $4.7 million, or $(0.36) per diluted share, and non-GAAP adjusted net income of $2.8 million, or $0.21 per diluted share
      • Non-GAAP specialty finance net income per share of $4.8 million, or $0.37 per diluted share for the quarter ended March 31, 2020, as compared to $7.4 million, or $0.57 per diluted share, for the quarter ended March 31, 2019, which included $3.5 million, or $0.27 per diluted share, income related to exit and prepayment fees received from a loan payoff during the quarter ended March 31, 2019
      • Tangible financing book value per share of $14.75 as of March 31, 2020, which excludes the deferred tax asset, intangible assets, goodwill, property and equipment and contingent consideration payable
      • Deployed $5.5 million to two existing borrowers during the quarter and an additional, $0.6 million to one existing borrower after the close of the quarter
      • As of March 31, 2020, SWK had approximately $24.3 million in cash and an additional $5.7 million availability remaining on a revolving credit facility

      SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a business update and announced its financial and operating results for the first quarter ended March 31, 2020.

      "SWK's focus on investing in differentiated, intellectual property-protected life science products and companies continued to demonstrate its strength during the first quarter as our business produced solid returns despite the ongoing macro challenges resulting from the COVID-19 outbreak," stated Winston Black, Chairman and CEO of SWK. "As the healthcare system begins to normalize, with essential procedures now being performed, and elective procedures beginning to resume at some hospitals, we believe that SWK is well positioned to address future demand from life science companies for the range of financial services that we provide."

      Mr. Black continued, "Our work with Enteris BioPharma also continues apace, and we are very pleased to report that the company has appointed a new CEO, Rajiv Khosla, Ph.D.  Dr. Khosla brings to Enteris a wealth of experience and expertise from a distinguished career as an industry executive and a consultant advising small biopharmaceutical companies, specifically regarding optimizing the monetization of intellectual property. His business development experience and proven track record, including direct experience with oral drug delivery technologies, will be critical to Enteris as the company seeks to capture more value-creating opportunities and maximize the potential of its Peptelligence® platform."

      COVID-19 Considerations

      Mr. Black commented, "As we reported previously, SWK continues to operate with minimal interruption resulting from the COVID-19 outbreak, and we remain well capitalized with approximately $30.0 million of cash and revolver availability to execute our recently re-authorized stock repurchase program and capitalize on new potential investment opportunities. Additionally, we believe our portfolio is well positioned given our focus on secured lending to small and mid-sized commercial-stage companies with differentiated technology and intellectual property.  However, we are continuously monitoring the potential impact of COVID-19 on the liquidity of our business partners and remain in regular contact with the individual management teams.  While the depth and duration of the COVID-19 impact is uncertain, we are enthused by the work of two of our portfolio companies, DxTerity Diagnostics and Biolase, which are actively contributing to our nation's fight against COVID-19 through innovative products and diagnostics."

      Mr. Black concluded, "Regarding Enteris, the majority of the company continues to abide by work-from-home directives as dictated by the State of New Jersey.  However, the laboratory and manufacturing facilities are open and operational, with employee hours being staggered to ensure proper social distancing.  While there has been an expected reduction in productivity and business development efforts, as well as delays in receiving some needed supplies due to the COVID-19 situation, we expect Enteris to generate positive cash flow above its expenses from proceeds received under its license agreements and customer relationships.  In this regard, we were pleased to see that in its first quarter 2020 update Cara Therapeutics, which previously entered into a licensing agreement with Enteris, re-affirmed key milestones for its three Oral Korsuva™ programs.  Notably, Cara remains on track to conduct an End of Phase 2 Meeting with the FDA to enable initiation of a Phase 3 program in the second half of 2020 for Oral Korsuva as a treatment for pruritus in patients with stage III-V (moderate-to-severe) chronic kidney disease.  Additionally, Cara expects to report top-line results in 2020 from its two Phase 2 clinical trials of Oral Korsuva in atopic dermatitis and pruritus in patients with hepatic impairment due to primary biliary cholangitis."

      First Quarter 2020 Financial Results

      For the first quarter 2020, SWK reported total revenue of $7.3 million compared to $9.4 million for the first quarter 2019. Revenue primarily consisted of interest and fees earned on our finance receivables as well as pharmaceutical development revenue generated by Enteris. The decrease in revenue was primarily due to a $3.5 million decrease in interest and fees earned on a finance receivable that was paid off during the first quarter of 2019, partially offset by approximately $1.2 million increase in interest and fees earned on new investments and increased funding to portfolio partners.

      Income (loss) before taxes for the first quarter 2020 totaled $(3.4) million compared to $7.7 million for the same period of the previous year.  The decline is driven by a $3.5 million expense for Enteris intangibles amortization and property and equipment depreciation, a $2.8 million expense as a result of fair market value declines of our equity-related positions, and a $2.0 million operating loss for Enteris (excluding amortization and depreciation expense).   

      The GAAP net (loss) income for the first quarter ended March 31, 2020 totaled $(4.7) million, or $(0.36) per diluted share, compared to $6.6 million, or $0.51 per diluted share for the first quarter 2019. For the first quarter 2020, adjusted net income was $2.8 million, or $0.21 per diluted share, compared to $7.4 million, or $0.57 per diluted share, for the first quarter 2019.

      Income producing assets (defined as finance receivables and corporate debt securities) totaled $178.3 million as of March 31, 2020.  This is an increase compared with income producing assets of $154.9 million as of March 31, 2019.

      Book value per share was $17.96 as of March 31, 2020, which includes $0.26 per share negative impact from the amortization of Enteris intangibles and $0.21 per share impact from mark-to-market changes on warrant and equity securities, compared to $18.31 as of December 31, 2019 and $16.98 as of March 31, 2019.  Tangible financing book value per share, which excludes the deferred tax asset, intangible assets, goodwill, property and equipment and contingent consideration payable, totaled $14.75 as of March 31, 2020.  Management views tangible financing book value per share as a relevant metric to value the company's core specialty finance business.      

      Tables detailing SWK's financial performance for the first quarter 2020 are below.

      Portfolio Status:

      During the first quarter 2020, the Company deployed $5.5 million in term loan financings, consisting of $2.5 million to existing borrower Aimmune Therapeutics and $3.0 million to existing borrower 4Web, Inc. Subsequent to the quarter end, the Company advanced $0.6 million to existing borrower Harrow Health.  At the end of the first quarter 2020, the weighted average projected effective yield of the finance receivables portfolio was 13.2%, including non-accrual positions, versus 14.2% as of the end of the first quarter in the previous year. The projected effective yield is the rate at which income is expected to be recognized pursuant to the Company's revenue recognition policies, if all payments are received pursuant to the terms of the finance receivables.

      Total portfolio investment activity for the three months ended March 31, 2020 and 2019 was as follows (in thousands):


      Three Months Ended March 31,


      (in thousands)

      2020


      2019


      Beginning Portfolio

      $178,648


      $169,919


      Early Payoffs

      -


      (20,000)


      Impairment Expense and Provision for Loan Credit Losses

      (163)


      (609)


      Interest Paid-in-Kind

      442


      406


      Investment in Finance Receivables

      5,500


      11,186


      Loan Discount Amortization and Fee Accretion (1)

      561


      681


      Net Unrealized Gain (Loss) on Marketable Investments and Warrant Assets

      (2,697)


      280


      Principal Payments Received on Investments

      (561)


      (906)


      Royalty (Paydowns) Accretion

      (804)


      (2,979)


      Ending Portfolio

      $180,926


      $157,978



      (1) Includes Interest Income in Excess of Cash Collected and Warrants Received

      Portfolio Updates Post Quarter End

      After the close of the first quarter 2020, the Company deployed $0.6 million to one existing borrower.  As of May 14, 2020, SWK had $6.3 million in unfunded commitments. 

      Uplisting Common Stock to Nasdaq
      On January 21, 2020, SWK Holdings announced that its shares of common stock were approved for listing on the Nasdaq Capital Market. Trading on the exchange commenced on January 23, 2020 under the ticker symbol "SWKH."

      Update on Enteris BioPharma

      • Dr. Rajiv Khosla Appointed Chief Executive Officer
        On May 4, 2020, SWK's wholly-owned subsidiary Enteris, announced the hiring of Rajiv Khosla, Ph.D., as Chief Executive Officer. Dr. Khosla replaced Joel Tune, Enteris' CEO since 2016.

        With more than 30 years of biopharmaceutical industry experience as both a consultant and senior corporate executive, Dr. Khosla is leading Enteris as the company targets multiple growth opportunities built around Peptelligence. Importantly, as CEO, Dr. Khosla will spearhead the advancement of Enteris' external and internal programs, as well as the development of new external licensing and partnership opportunities that leverage the company's Peptelligence platform.

      • Dr. Gary Shangold Named Chief Medical Officer
        On February 10, 2020, Enteris announced the hiring of Gary A. Shangold, M.D., as Chief Medical Officer (CMO). As CMO, Dr. Shangold is responsible for the advancement of Enteris' external and internal programs, as well as the development of new licensing and partnership opportunities that leverage the Peptelligence platform.

      Update on Share Repurchase Program
      On December 21, 2018, SWK's Board of Directors authorized a $3.5 million share repurchase program, totaling up to 312,491 common shares. The initial authorized purchase period was December 21, 2018 through May 31, 2019; however, the board reauthorized the share repurchase program in September 2019, which extended through February 29, 2020.  In March 2020 the Board authorized a new program for the repurchase of up to an aggregate of $2.0 million of the Company's common shares from time to time through a "10b5-1 trading plan" in compliance with Rule 10b-18 under the Securities Exchange Act of 1934.  This program will expire on September 30, 2020 and replaces the program that expired on February 29, 2020. In the aggregate, SWK has repurchased 243,845 shares since commencing the initial repurchase program through May 13, 2020.

      Adjusted Non-GAAP Net Income
      Net loss in accordance with GAAP for the three-month period ended March 31, 2020, was $4.7 million, or $(0.36) per diluted share.

      The following table provides a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated net income (Non-GAAP) for the three-month periods ended March 31, 2020 and March 31, 2019.  The table eliminates provisions for income taxes, non-cash mark-to-market changes on warrant assets and equity securities, and amortization of Enteris intangible assets.

      (in thousands, except per share data)

      Three Months Ended
      March 31,



      2020


      2019


      Consolidated net (loss) income

      $(4,660)


      $6,559


      Plus: income tax expense

      1,253


      1,111


      Plus: loss on fair market value of equity securities

      890


      -


      Plus (Subtract): (gain) loss on fair market value of warrant assets

      1,860


      (258)


      Plus: Enteris intangibles amortization

      3,414


      -


      Adjusted income before provision for income taxes

      2,757


      7,412


      Adjusted provision for income taxes

      -


      -


      Non-GAAP consolidated net income

      $2,757


      $7,412


      Non-GAAP adjusted basic income per share

      $0.21


      $0.57


      Non-GAAP adjusted diluted income per share

      $0.21


      $0.57


      Weighted Average Shares – Basic

      12,913


      12,906


      Weighted Average Shares – Diluted

      12,923


      12,909


      In the table above, management has deducted the following non-cash items: (i) change in the fair-market value of equities and warrants as mark-to-market changes are non-cash, (ii) income taxes as the Company has substantial net operating losses to offset against future income, and (iii) amortization expense associated with Enteris intangible assets.

      Specialty Finance Adjusted Non-GAAP Net Income
      The following table provides a reconciliation of SWK's consolidated adjusted income before provision for income taxes, listed in the table above, to the non-GAAP adjusted net income for the specialty finance business for the three month period ended March 31, 2020.  The table eliminates expenses associated with the acquisition of Enteris, and Enteris operating losses. The adjusted income before the provision for income taxes is derived in the table above and eliminates provisions for income taxes, non-cash mark-to-market changes on warrant assets and equity securities.

      (in thousands, except per share data)

      Three Months Ended
      March 31,



      2020


      2019


      Adjusted income before provision for income taxes

      $2,757


      $7,412


      Plus: Enteris acquisition expense

      -


      -


      Plus: Enteris operating loss excluding depreciation and amortization

      2,031


      -


      Adjusted specialty finance income before provision for income taxes

      $4,788


      $7,412


      Adjusted provision for income taxes

      -


      -


      Non-GAAP specialty finance net income

      $4,788


      $7,412


      Non-GAAP adjusted basic income per share

      $0.37


      $0.57


      Non-GAAP adjusted diluted income per share

      $0.37


      $0.57


      Weighted Average Shares – Basic

      12,913


      12,906


      Weighted Average Shares – Diluted

      12,923


      12,909


      Conference Call Information:

      SWK Holdings will host a conference call and live audio webcast on Friday, May 15, 2020, at 10:00 a.m. ET, to discuss its corporate and financial results for the first quarter 2020. Interested participants and investors may access the conference call by dialing either:

      • (877) 870-4263 (U.S.)
      • (412) 317-0790 (international)

      An audio webcast will be accessible via the Investor Relations section of the Company's website https://www.swkhold.com/. An archive of the webcast will remain available for 90 days beginning at approximately 11:00 a.m. ET, on May 15, 2020.

      Non-GAAP Financial Measures
      This release includes non-GAAP adjusted net income and non-GAAP specialty finance net income , which are not metrics that are compliant with generally accepted accounting principles in the United States (GAAP).  Non-GAAP adjusted net income is adjusted for certain items (including (i) changes in the fair-market value of public equity-related assets and SWK's warrant assets as mark-to-market changes are non-cash, (ii) income taxes as the Company has substantial net operating losses to offset against future income, and (iii) depreciation and amortization expenses, primarily associated with the Enteris acquisition). In addition to the adjustments noted above, non-GAAP specialty finance net income also excludes Enteris operating losses. These non-GAAP measures may not be directly comparable to similar measures used by other companies in our industry, as other companies may define such measures differently. Management believes that these measures are useful to investors and management in understanding our ongoing operations and in analysis of ongoing operating trends and provides useful additional information relating to our operations and financial condition. These metrics should be considered in addition to, and not as a replacement for, the most comparable GAAP measure.

      About SWK Holdings Corporation
      SWK Holdings Corporation is a specialty finance company with a focus on the global healthcare sector. SWK partners with ethical product marketers and royalty holders to provide flexible financing solutions at an attractive cost of capital to create long-term value for both SWK's business partners and its investors. SWK believes its financing structures achieve an optimal partnership for companies, institutions and inventors seeking capital for expansion or capital and estate planning by allowing its partners to monetize future cash flow with minimal dilution to their equity stakes. SWK also owns Enteris Biopharma, whose core Peptelligence® drug delivery technology creates oral formulations of peptide-based and BCS class II, III, and IV small molecules. With Enteris, SWK has the opportunity to grow its specialty finance business by actively building a wholly-owned portfolio of milestones and royalties through licensing activities.  Additional information on the life science finance market is available on the Company's website at www.swkhold.com.

      Safe Harbor Statement
      This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect SWK's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" and elsewhere in SWK's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the Company's actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

      SWK HOLDINGS CORPORATION

      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

      (in thousands, except par value and share data)



      March 31,
      2020


      December 31,
      2019

      ASSETS




      Current assets:




      Cash and cash equivalents

      $

      24,318



      $

      11,158


      Interest and accounts receivable, net

      2,011



      2,554


      Marketable investments

      912



      1,802


      Other current assets

      1,548



      1,087


      Total current assets

      28,789



      16,601






      Finance receivables, net

      177,981



      172,825


      Marketable investments

      285



      466


      Deferred tax asset, net

      24,527



      25,780


      Warrant assets

      1,748



      3,555


      Intangible assets, net

      21,796



      25,113


      Goodwill

      8,404



      8,404


      Property and equipment, net

      1,299



      1,292


      Other non-current assets

      290



      336


      Total assets

      $

      265,119



      $

      254,372






      LIABILITIES AND STOCKHOLDERS' EQUITY




      Current liabilities:




      Accounts payable and accrued liabilities

      $

      4,068



      $

      3,061


      Revolving credit facility

      14,288



      —


      Total current liabilities

      18,356



      3,061






      Contingent consideration payable

      14,500



      14,500


      Warrant liability

      129



      76


      Other non-current liabilities

      137



      203


      Total liabilities

      33,122



      17,840






      Stockholders' equity:




      Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

      —



      —


      Common stock, $0.001 par value; 250,000,000 shares authorized; 12,918,006 and 12,917,348 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

      13



      13


      Additional paid-in capital

      4,432,271



      4,432,146


      Accumulated deficit

      (4,200,287)



      (4,195,627)


      Total stockholders' equity

      231,997



      236,532


      Total liabilities and stockholders' equity

      $

      265,119



      $

      254,372


      SWK HOLDINGS CORPORATION

      UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF (LOSS) INCOME

      (in thousands, except per share data)



      Three Months Ended
      March 31,


      2020


      2019

      Revenues:




      Finance receivables interest income, including fees

      $

      7,136



      $

      9,391


      Pharmaceutical development

      148



      —


      Other

      18



      1


      Total revenues

      7,302



      9,392


      Costs and expenses:




      Provision for credit losses

      —



      609


      Impairment expense

      163



      —


      Interest expense

      101



      102


      Pharmaceutical manufacturing, research and development expense

      1,150



      —


      Depreciation and amortization expense

      3,505



      5


      General and administrative

      3,040



      1,264


      Total costs and expenses

      7,959



      1,980


      Other (expense) income, net




      Unrealized net (loss) gain on warrants

      (1,860)



      258


      Unrealized net loss on equity securities

      (890)



      —


      (Loss) income before provision for income taxes

      (3,407)



      7,670


      Provision for income taxes

      1,253



      1,111


      Consolidated net (loss) income

      $

      (4,660)



      $

      6,559


      Net (loss) income per share




      Basic

      $

      (0.36)



      $

      0.51


      Diluted

      $

      (0.36)



      $

      0.51


      Weighted Average Shares




      Basic

      12,913



      12,906


      Diluted

      12,913



      12,909


      SWK HOLDINGS CORPORATION

      UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

      (in thousands)



      Three Months Ended
      March 31,


      2020


      2019

      Cash flows from operating activities:




      Consolidated net (loss) income

      $

      (4,660)



      $

      6,559


      Adjustments to reconcile net (loss) income to net cash provided by operating activities:




      Provision for loan credit losses

      —



      609


      Security impairment expense

      163



      —


      Amortization of debt issuance costs

      47



      —


      Deferred income taxes

      1,253



      1,111


      Change in fair value of warrants

      1,860



      (258)


      Change in fair value of equity securities

      890



      —


      Loan discount amortization and fee accretion

      (536)



      (600)


      Interest paid-in-kind

      (467)



      (406)


      Stock-based compensation

      187



      102


      Interest income in excess of cash received

      —



      (82)


      Depreciation and amortization expense

      3,505



      —


      Changes in operating assets and liabilities:




      Interest and accounts receivable, net

      543



      265


      Other assets

      (462)



      (9)


      Accounts payable, accrued liabilities and other liabilities

      994



      (291)


      Net cash provided by operating activities

      3,317



      7,000






      Cash flows from investing activities:




      Investment in finance receivables

      (5,500)



      (11,186)


      Repayment of finance receivables

      1,348



      23,866


      Corporate debt security principal payment

      18



      21


      Other

      (249)



      —


      Net cash (used in) provided by investing activities

      (4,383)



      12,701






      Cash flows from financing activities:




      Net proceeds from credit facility

      14,288



      —


      Repurchases of common stock, including fees and expenses

      (62)



      (745)


      Net cash provided by (used in) financing activities

      14,226



      (745)






      Net increase in cash and cash equivalents

      13,160



      18,956


      Cash and cash equivalents at beginning of period

      11,158



      20,227


      Cash and cash equivalents at end of period

      $

      24,318



      $

      39,183


      SOURCE SWK Holdings Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.